BGB-3111-212

Active, not recruiting

A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

Beigene Study ID info

BGB-3111-212

ClinicalTrials.gov ID info

EudraCT Number info

2017-001552-54

Study Overview

Sex: All

Age: 18 Years to 99 Years (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents

Study Overview

Sex: All

Age: 18 Years to 99 Years (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents